University of Wisconsin–Madison

Cancer Biology Seminar Series: Dave Vereide, PhD

This event has passed.

1345 HSLC

Arming induced pluripotent stem cells with a synthetic receptor enables the scalable manufacture of highly cytotoxic lymphocytes for “off-the-shelf” cancer immunotherapies Dave Vereide, PhD Principal Scientist Umoja Biopharma